Acacia Technologies Acquires Rights to Patents for Purifying Nucleic Acids
News Jun 11, 2007
Acacia Research Corporation has announced that Acacia Patent Acquisition Corporation, a wholly owned subsidiary that is part of the Acacia Technologies group has acquired rights to patents relating to purifying nucleic acids.
"As Acacia's licensing success grows, more companies are selecting us as their partner for the licensing of their patented technologies," commented Paul Ryan, Acacia Chairman and CEO. "Acacia is rapidly becoming the leader in technology licensing and we continue to grow our base of future revenues by adding new patent portfolios,” concluded Mr. Ryan.
These patents generally relate to methods and equipment used to purify plasmid DNA products. This technology may be used in the production of ultrapure pharmaceutical quality nucleic acids for DNA-vaccines and gene therapies. The technology is applicable to biotech products for a wide variety of diseases.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.